Q-omics provides the consensus-scored LIPT1 profile across patient tissues and cancer cell-line models. LIPT1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LIPT1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, LIPT1 RNA expression shows 20,353 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, THCA, and UVM as cancer lineages where LIPT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIPT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIPT1 survival associations across molecular data types. LIPT1 RNA expression shows survival associations in the most cancer types (28), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIPT1 RNA expression–survival associations across cancer types. High LIPT1 expression shows unfavorable associations in SCLC, LIHC, KICH and UCEC, but favorable associations in BLCA and LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LIPT1 RNA expression.
This table summarizes LIPT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LIPT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIPT1 shows lower tumor expression in THCA, KICH, UCEC and BRCA and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher LIPT1 RNA expression in normal versus tumor tissue (log2 FC = −0.603, t-test p < 0.001).
This table shows molecular features associated with LIPT1 in patient tissues and cancer cell lines. In patient samples, LIPT1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LIPT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
